3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Obesity
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Fatty Liver
1
Burkitt Lymphoma
1
Interventions
penclomedine
1
atezolizumab
1
Triptorelin Pamoate
1
Orchiectomy
1
Olive Oil
1
Metformin
1
Exenatide
1
Excitatory Amino Acids
1
Diet, Ketogenic
1
Bevacizumab
1
Amino Acids, Essential
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Fatty Liver
×
penclomedine
×
Clear all
NCT02157974
2024-06-04
APPLE
University of Colorado, Denver
Phase 2/3
Completed
92 enrolled
17 charts